Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion.

Garg H, Joshi A, Freed EO, Blumenthal R.

J Biol Chem. 2007 Jun 8;282(23):16899-906. Epub 2007 Apr 6.

2.
3.

HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells.

Denizot M, Varbanov M, Espert L, Robert-Hebmann V, Sagnier S, Garcia E, Curriu M, Mamoun R, Blanco J, Biard-Piechaczyk M.

Autophagy. 2008 Nov;4(8):998-1008. Epub 2008 Nov 1.

PMID:
18818518
4.

Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.

Dimitrov AS, Rawat SS, Jiang S, Blumenthal R.

Biochemistry. 2003 Dec 9;42(48):14150-8.

PMID:
14640682
5.
6.

Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events.

Blanco J, Barretina J, Ferri KF, Jacotot E, Gutiérrez A, Armand-Ugón M, Cabrera C, Kroemer G, Clotet B, Esté JA.

Virology. 2003 Jan 20;305(2):318-29.

7.
8.

HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.

Joshi A, Nyakeriga AM, Ravi R, Garg H.

J Biol Chem. 2011 Oct 21;286(42):36404-13. doi: 10.1074/jbc.M111.281659. Epub 2011 Aug 22.

10.

Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.

Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA.

J Virol. 2005 Oct;79(19):12231-41.

13.

Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infection.

Chen SS, Yang P, Ke PY, Li HF, Chan WE, Chang DK, Chuang CK, Tsai Y, Huang SC.

J Virol. 2009 Jan;83(2):870-83. doi: 10.1128/JVI.01088-08. Epub 2008 Nov 5.

15.

Evaluation of the cytopathicity (fusion/hemifusion) of patient-derived HIV-1 envelope glycoproteins comparing two effector cell lines.

Cunyat F, Curriu M, Marfil S, García E, Clotet B, Blanco J, Cabrera C.

J Biomol Screen. 2012 Jul;17(6):727-37. doi: 10.1177/1087057112439890. Epub 2012 Mar 16.

PMID:
22427259
16.

Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants.

Garg H, Joshi A, Blumenthal R.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):811-7. doi: 10.1089/aid.2009.0010.

17.

HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development.

Jacobs A, Garg H, Viard M, Raviv Y, Puri A, Blumenthal R.

Vaccine. 2008 Jun 6;26(24):3026-35. doi: 10.1016/j.vaccine.2007.12.026. Epub 2008 Jan 10.

18.

Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis.

Garg H, Blumenthal R.

Cell Mol Life Sci. 2008 Oct;65(20):3134-44. doi: 10.1007/s00018-008-8147-6. Review.

19.

Caveolin-1 modulates HIV-1 envelope-induced bystander apoptosis through gp41.

Wang XM, Nadeau PE, Lo YT, Mergia A.

J Virol. 2010 Jul;84(13):6515-26. doi: 10.1128/JVI.02722-09. Epub 2010 Apr 14.

20.

Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.

Garg H, Viard M, Jacobs A, Blumenthal R.

Curr Top Med Chem. 2011 Dec;11(24):2947-58. Review.

Supplemental Content

Support Center